- Home
- TVTX vs SLNO Comparison
TVTX vs SLNO Comparison
Compare TVTX & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVTX
- SLNO
- Stock Information
- Founded
- TVTX 2008
- SLNO 1999
- Country
- TVTX United States
- SLNO United States
- Employees
- TVTX N/A
- SLNO N/A
- Industry
- TVTX Biotechnology: Pharmaceutical Preparations
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- TVTX Health Care
- SLNO Health Care
- Exchange
- TVTX Nasdaq
- SLNO Nasdaq
- Market Cap
- TVTX 3.1B
- SLNO 3.7B
- IPO Year
- TVTX N/A
- SLNO 2014
- Fundamental
- Price
- TVTX $35.18
- SLNO $47.14
- Analyst Decision
- TVTX Strong Buy
- SLNO Strong Buy
- Analyst Count
- TVTX 15
- SLNO 9
- Target Price
- TVTX $37.21
- SLNO $114.89
- AVG Volume (30 Days)
- TVTX 2.1M
- SLNO 2.3M
- Earning Date
- TVTX 10-30-2025
- SLNO 11-04-2025
- Dividend Yield
- TVTX N/A
- SLNO N/A
- EPS Growth
- TVTX N/A
- SLNO N/A
- EPS
- TVTX N/A
- SLNO N/A
- Revenue
- TVTX $435,826,000.00
- SLNO $98,675,000.00
- Revenue This Year
- TVTX $108.68
- SLNO N/A
- Revenue Next Year
- TVTX $40.23
- SLNO $181.30
- P/E Ratio
- TVTX N/A
- SLNO N/A
- Revenue Growth
- TVTX 114.22
- SLNO N/A
- 52 Week Low
- TVTX $12.91
- SLNO $41.50
- 52 Week High
- TVTX $36.76
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- TVTX 66.12
- SLNO 35.53
- Support Level
- TVTX $33.05
- SLNO $46.82
- Resistance Level
- TVTX $36.76
- SLNO $50.04
- Average True Range (ATR)
- TVTX 1.95
- SLNO 3.71
- MACD
- TVTX -0.02
- SLNO -1.16
- Stochastic Oscillator
- TVTX 80.99
- SLNO 17.66
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.